AnaptysBio Inc (ANAB)vsBeiGene, Ltd. (ONC)
ANAB
AnaptysBio Inc
$65.39
+3.76%
HEALTHCARE · Cap: $1.88B
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 2177% more annual revenue ($5.34B vs $234.60M). ONC leads profitability with a 5.4% profit margin vs -5.6%. ONC earns a higher WallStSmart Score of 42/100 (D).
ANAB
Hold38
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ANAB.
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 61.8%
Revenue surging 151.1% year-over-year
Conservative balance sheet, low leverage
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 49.2x book value
ROE of -24.5% — below average capital efficiency
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : ANAB
The strongest argument for ANAB centers on Operating Margin, Revenue Growth, Debt/Equity. Revenue growth of 151.1% demonstrates continued momentum.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : ANAB
The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Key Dynamics to Monitor
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ANAB is growing revenue faster at 151.1% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 38/100) and 32.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AnaptysBio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Visit Website →BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?